Cite
MLA Citation
Olivier Mir et al.. “Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.” Lancet oncology, vol. 17, no. 5, n.d., pp. 632–641. http://access.bl.uk/ark:/81055/vdc_100032015727.0x00000d